TIGIT and neoplasm: Third, the TIGIT on the surface of tumor-infiltrating CD8+T cells competitively binds to the PVR on the surface of tumor cells or dendritic cells, resulting in the failure of T cell-activated receptor CD226 to bind to PVR, thus inhibiting the activity of T cells (43).